Close Menu

NEW YORK (GenomeWeb) – Asuragen said today that it is collaborating with Thermo Fisher Scientific to develop and commercialize capillary electrophoresis-based in vitro diagnostics.

Asuragen, based in Austin, Texas, will develop diagnostic kits for Thermo Fisher’s 3500 Dx Series Genetic Analyzer CS2 instrument, using its AmplideX PCR/CE technology, which enables the analysis of repetitive DNA sequences, and its AmplideX Reporter analytics and reporting software. The products will be built under design control and manufactured at Asuragen's cGMP facility.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.